Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
Rank Status Study
21 Unknown  Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
Conditions: Cytomegalovirus Infections;   Adenovirus Infections
Intervention: Other: Cell therapy
22 Recruiting A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
Conditions: Adenovirus Infection;   EBV;   Cytomegalovirus Infections;   Cytokine Capture System®;   Allogenic Disease
Intervention: Biological: IFN-γ positive selected T-cells
23 Recruiting MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Condition: Cytomegalovirus Infections
Interventions: Drug: MK-8228;   Drug: Placebo
24 Unknown  Cytomegalovirus (CMV) Infection in Amniotic Fluid
Conditions: Pregnancy Complications;   Cytomegalovirus Infections
Intervention:
25 Recruiting Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Condition: Cytomegalovirus Infections
Interventions: Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
26 Recruiting Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Condition: Cytomegalovirus Infections
Intervention: Biological: CMV Specific T Cell donor lymphocyte infusion
27 Not yet recruiting Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Condition: Cytomegalovirus Infections
Intervention: Biological: IFN-γ positive selected T-cells
28 Recruiting Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
Conditions: Transplantation Infection;   Cytomegalovirus Infections
Interventions: Drug: Everolimus;   Drug: Very Low Tacrolimus;   Drug: Low Tacrolimus;   Drug: Steroids;   Drug: Thymoglobulin;   Drug: Sodium Mycophenolate
29 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Kidney Transplantation;   Epstein-Barr Virus Infections/Complications;   Cytomegalovirus Infections/Complications
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
30 Recruiting An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Condition: Cytomegalovirus Infections, Transplantation
Intervention:
31 Recruiting Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: Standardized test report
32 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
33 Not yet recruiting Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
Condition: Congenital Cytomegalovirus Infection
Interventions: Drug: Valacyclovir;   Drug: Placebo
34 Unknown  T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
Conditions: Graft Versus Host Disease;   Nonneoplastic Condition
Interventions: Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
35 Not yet recruiting Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Condition: CMV Infections
Intervention: Biological: Viralym-C
36 Recruiting TT-CMV Observational Birth Cohort Study
Condition: Cytomegalovirus Disease
Intervention:
37 Recruiting Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients
Condition: Cytomegalovirus Disease
Interventions: Other: Preemptive Therapy;   Drug: Prophylaxis with Valganciclovir
38 Not yet recruiting Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy
Conditions: Congenital Cytomegalovirus;   Hearing Loss
Interventions: Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
39 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
40 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-52) Show next page of results    Last Page
Indicates status has not been verified in more than two years